Health Canada approved Imbruvica (ibrutinib) as an oral, once-daily, single-agent targeted therapy for previously untreated patients with active chronic lymphocytic leukemia. This is the fourth Canadian approval for Imbruvica, which is now approved for use in all lines of CLL therapy.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
